Compatibility of vaginal beneficial lactic acid bacteria (vblab) with phytoderivatives for the design of phytobiotic formulas

ANTONELLA MARCHESI; M.E.FATIMA NADER; JESSICA SILVA

San Miguel de Tucuman

Simposio; V Congreso Internacional de Bacterias Lacticas (SIBAL); 2016

CERELA

Lactobacillus are the most predominant microorganisms in the healthy vaginal microbioma, and exert a wide diversity of physiology functions directed to maintain the ecological equilibrium and protect the reproductive health. The urogenital tract infections are the most common cause of attendance to gynecologist consult, being frequently treated with antibiotics. Probiotic and phytoderivative formulations are applied for prevention and therapy of chronic syndromes. Our research group is working on the design of a phytobiotic formulation, defined as a ?product that includes probiotics combined with other substances with different functionalities (phytoderivatives) able to interact beneficially with the host?. The objective of this work was to determine the compatibility of VBLAB and vegetal derivatives frequently applied by the oral or vaginal route for the prevention of urogenital tract infections. . The evaluation was performed with different lactobacilli species (Lactobacillus reuteri, L. gasseri, L. rhamnosus, L. salivarius) and phytoderivates approved by the Pharmacopeia for human uses: a) oral administration: Atropa Belladona, Peumus boldo, B) mucosal application: Thymus vulgaris, C) both ways: Cranberry, Hydrocotyle asiática, Echinacea angustifolia, Allium sativum, Arctostaphylos uva-ursi, Matricaria recutita L and Lapacho. The inhibition assays were performed by the plate diffusion technique, by inoculation of different concentrations of VBLAB (107 CFU/plate) in the agar and wells filled with phytobiotics (serial dilutions from 30mg/ml), incubated in microaerophylic conditions at 37°C. The inhibitory halos were measured after 48 h incubation. Also, the growth of the strains (106 CFU/well) together with phytocompounds (serial dilutions from 150 ug/well) was evaluated in polystyrene microplates by optical density (OD560nm) at 3, 6, 9, 12, 24 h at 37°C. Growth curves were plotted to determine the behavior of each strain. The results indicate that most of the phytocompounds did not inhibit the VBLAB at 107 y 106 UFC, except in the case of A. uva-ursi (8-18 mm) and Hamamelis (7-9 mm), being A. uva-ursi the most inhibitory compound for all the VBLAB strains assayed. Referred to the effect on the bacterial growth, Echinacea (18 %), Hamamelis (15%), Lapacho (16 %) and A. uva-ursi (28 %) inhibited L. gasseri CRL 1320, while L. gasseri CRL 1237 L. reuteri CRL 1324 and CRL 1327, L. rhamnosus CRL 1508, CRL 1511 and CRL 1332, and L. salivarius CRL 1328 were not affected by the lower phytoconcentration concentration (37ug) but a slight decrease of bacterial growth was observed with higher concentration of A. uva-ursi, Hamamelis and Lapacho. The results obtained support the phytoderivatives approved by the Pharmacopeia that could be combined with the VBLAB for the design of phytobiotic formulations that should be administered by vaginal or oral route.